Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00196755 |
Recruitment Status :
Completed
First Posted : September 20, 2005
Last Update Posted : March 18, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Peritoneal Dialysis Chronic Kidney Disease | Drug: Sevelamer Hydrochloride (Renagel®) Drug: Calcium acetate (PhosLo® ) | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 138 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride (Renagel®) Compared With Calcium Acetate in Peritoneal Dialysis Patients |
Study Start Date : | December 2004 |
Actual Primary Completion Date : | March 2006 |
Actual Study Completion Date : | April 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: Sevelamer Hydrochloride (Renagel®) |
Drug: Sevelamer Hydrochloride (Renagel®)
Sevelamer hydrochloride three times per day with each meal |
Active Comparator: Calcium acetate (PhosLo® ) |
Drug: Calcium acetate (PhosLo® )
Calcium acetate three times per day with each meal |
- Compare the effects of sevelamer dosed three times per day (TID) and calcium acetate dosed TID on serum phosphorus. [ Time Frame: 12 weeks ]
- Serum calcium- phosphorus (CaxPO4) product [ Time Frame: 12 weeks ]
- Serum lipids - total and LDL cholesterol, non- HDL cholesterol, HDL, triglycerides [ Time Frame: 12 weeks ]
- Plasma biomarkers: random blood glucose, glycosylated haemoglobin, bone specific alkaline phosphatase, uric acid and c-reactive protein [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Willing and able to sign an informed consent form.
- Men or women aged 18 years of age or older.
- A diagnosis of Chronic Kidney Disease (CKD) and receiving peritoneal dialysis (Continuous cyclical peritoneal dialysis (CAPD), Automated peritoneal dialysis (APD) or Continuous cyclical peritoneal dialysis (CCPD) for 8 weeks or longer.
- In the opinion of the investigator, expected to receive peritoneal dialysis for the duration of the study.
- Will have a serum phosphorus level >1.76 mmol/L(5.50 mg/dL) after 2 weeks washout from their usual phosphate binder.
- Will have serum calcium measurement adjusted for albumin within the range (2.10-2.60 mmol/L (8.40-10.40 mg/dL) following 2 weeks washout from their usual phosphate binder.
- Willing to maintain the prescribed sevelamer or calcium acetate for the duration of the study.
- Considered compliant with phosphate binders and dialysis.
- On a stable doses of medication to treat hyperparathyroidism (Vitamin D or its analogues or calcimimetic agents) for the month prior to screening.
- Willing to discontinue use of antacids containing calcium, aluminium or magnesium at screening visit for the duration of the study (unless taken as an evening calcium supplement as prescribed by the investigator per protocol).
- Willing to avoid intentional changes in diet such as fasting or dieting.
- If female and of childbearing potential (pre-menopausal and not surgically sterile), willing to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or Intrauterine devices (IUDs).
- Have a level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel.
Exclusion Criteria:
- Patients with a history of peritonitis in the last 30 days or > 2 episodes in the last 12 months
- Patient with active dysphagia, swallowing disorder, bowel obstruction, or severe gastrointestinal motility disorder.
- Patients who in the opinion of the investigator have poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, Human Immunodeficiency Virus (HIV) infection, or any clinically significant, unstable medical condition.
- Patients with any evidence of active malignancy except for basal cell carcinoma of the skin. A history of malignancy is not exclusion.
- Current use of an antiarrhythmic medication such as quinidine, procainamide, tocainide, or amiodarone for the control of arrhythmias.
- Current use of a seizure medication such as phenytoin, phenobarbital, valproate, or carbamazepine for the control of a seizure disorder.
- Active ethanol or drug abuse, excluding tobacco use.
- If female, are pregnant, planning on becoming pregnant in the next 6 months or breast-feeding.
- Patients with a known hypersensitivity to sevelamer or any constituents of either study drug.
- Patients who have participated in a study of an investigational drug/device during the 30 days preceding the start of the screening period.
- Patients who have any other condition, which in the opinion of the investigator will prohibit the patient's participation in the study.
- Patient is unable to comply with the requirements of the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00196755

Study Director: | Medical Monitor | Genzyme, a Sanofi Company |
Responsible Party: | Medical Monitor, Genzyme Corporation |
ClinicalTrials.gov Identifier: | NCT00196755 |
Other Study ID Numbers: |
REN00304 |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | March 18, 2015 |
Last Verified: | March 2015 |
Kidney Diseases Renal Insufficiency, Chronic Urologic Diseases Renal Insufficiency Calcium Sevelamer |
Calcium acetate Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action |